Dec 26, 2024 · Both Lilly and Novo Nordisk are experiencing unprecedented growth thanks to their weight loss medications. However, Lilly also treats cancer, plaque psoriasis, Alzheimer's disease, eczema,...

Oct 16, 2024 · The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of notable wins have me thinking this lead will widen.

Jan 3, 2025 · Novo Nordisk’s GLP-1s outsell Eli Lilly’s thanks to its superior marketing. Here’s how. In a market driven by innovation, it’s counterintuitive to see a company with a less effective product outperform its competitors—unless, of course, the answer lies in marketing.

Jan 14, 2025 · As of 10:45 a.m. ET, Lilly shares are shedding 6%. Archrival Novo Nordisk (NVO -0.52%) is down 3.3% in sympathy, while Viking Therapeutics (VKTX -3.01%), which is hard at work on its own GLP-1...

Apr 25, 2023 · While Novo Nordisk is probably the better weight-management stock, a more diverse product lineup and development pipeline make Eli Lilly the better overall pharmaceutical business.

Dec 20, 2024 · The two leading weight-loss drugs today are Wegovy from Novo Nordisk and Zepbound from Eli Lilly. Together, they are expected to generate about $44.6 billion in sales in 2029, the latest year...

May 15, 2024 · The mass interest in GLP-1 drugs has led to a business boom for the two dominant pharmaceutical players in this space, Lilly and Novo Nordisk, which sold over $7.3 billion worth of its GLP-1...

Aug 8, 2023 · Shares of pharmaceutical giant Eli Lilly skyrocketed to a record high on Tuesday, after the company reported a surge in sales of its diabetes and weight loss drug Mounjaro, while shares of rival...

Eli Lilly stock and Novo Nordisk shares haven't had a smooth year, but events in the fourth quarter widened the gap between the weight-loss drugmakers.

While Lilly and Novo Nordisk have each been approved to treat weight loss, it's important to understand the finer details of their respective medications.